Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin ...

Abbott Laboratories ABT recently received FDA approval for its Volt PFA System to treat patients battling atrial fibrillation (AFib). The company is expected to begin commercial PFA cases in the ...

US FDA approves Abbott's Volt PFA System to treat patients with atrial fibrillation: Abbott Park, Illinois Wednesday, December 24, 2025, 12:00 Hrs [IST] Abbott, is a global health ...

Atrial fibrillation (AFib) can lead to blood clots, stroke, heart failure, and other heart-related complications. New consumer patient research from the Dallas-based American Heart Association found ...

Barbara Dowell never liked taking blood-thinners. Sure, the anti-coagulant drug warfarin helped fend off the threat of strokes for the 74-year-old Dowell, who suffers from atrial fibrillation. But ...

Atrial fibrillation (AFib) is a type of heart arrhythmia that causes the top chambers of your heart, the atria, to quiver and beat irregularly. AFib used to be described as chronic or acute, with ...

Atrial fibrillation happens most often in older adults and in people with other heart problems. But it also affects younger people. Roughly 800,000 Americans under age 40 have atrial fibrillation, ...

Abbott (ABT) announced the U.S. FDA has approved the company’s Volt PFA System to treat patients battling atrial fibrillation ...